REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) — Pulmo x Co po atio (Nasdaq: LUNG) (“Pulmo x”), a global leade i mi imally i vasive t eatme ts fo lu g disease, today a ou ced that it will elease fi a cial esults fo the seco d qua te of 2026 afte the close of t adi g o Wed esday, July 29, 2026. Compa y ma ageme t will host a co fe e ce call to discuss fi a cial esults begi i g at 1:30 p.m. PT / 4:30 p.m. ET.
A live a d a chived webcast of the eve t will be available o the “I vesto s” sectio of the Pulmo x website at https://i vesto s.pulmo x.com/.
About Pulmo x Co po atio Pulmo x Co po atio (Nasdaq: LUNG) is a global leade i mi imally i vasive t eatme ts fo ch o ic obst uctive pulmo a y disease (COPD). Pulmo x’s Zephy ® E dob o chial Valve, Cha tis® Pulmo a y Assessme t System a d St atX® Lu g A alysis Platfo m a e desig ed to assess a d t eat patie ts with seve e emphysema/COPD who despite medical ma ageme t a e still p ofou dly symptomatic. Pulmo x eceived FDA p e-ma ket app oval to comme cialize the Zephy Valve followi g its desig atio as a “b eakth ough device.” The Zephy Valve is comme cially available i mo e tha 25 cou t ies, is i cluded i global t eatme t guideli es a d is widely co side ed a sta da d of ca e t eatme t optio fo imp ovi g b eathi g, activity a d quality of life i patie ts with seve e emphysema. Fo mo e i fo matio o the Zephy Valves a d the compa y, please visit www.pulmo x.com.
Pulmo x®, Cha tis®, St atX®, a d Zephy ® a e egiste ed t adema ks of Pulmo x Co po atio .
About Web3Wire Web3Wire – Information, news, press releases, events and research articles about Web3, Metaverse, Blockchain, Artificial Intelligence, Cryptocurrencies, Decentralized Finance, NFTs and Gaming. Visit Web3Wire for Web3 News and Events,Block3Wire for the latest Blockchain news and Meta3Wire to stay updated with Metaverse News.
Vmake Labs b i gs togethe eady-made Hallowee video templates, UGC-style p oduct fo mats, a d AI video a d image ge e atio to help small busi esses tu p oduct assets a d campaig ideas i to seaso al social media co te t PALO ALTO, Calif.,...
U.S. Chambe of Comme ce Fou datio ames estau a t decisio i tellige ce compa y a fi alist fo Best Sustai ability P og am CHICAGO, IL / ACCESS Newswi e / Octobe 23, 2026 / Clea COGS, a decisio i tellige ce compa y that tu s...
Fu di g will expa d p actice ma ageme t tech ology, ma aged billi g a d data mig atio se vices, a d i ovative cli ical tools fo pediat ic the apy p actices. NASHVILLE, TN / ACCESS Newswi e / Octobe 23, 2026 / Ambiki...
Fo me Nokia lice si g executive Robe t T. B au joi s i dust y leade s at IAM Live as Digitalage p epa es its fi st e te p ise-lice si g ca didate a d c eato -platfo m lau ch TEMECULA, CA / ACCESS...
Va couve , B itish Columbia, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Rocket Docto AI I c. (CSE: AIDR, OTC: AIRDF, F a kfu t: 939) (“Rocket Docto AI” o the “Compa y”) a ou ces that it has g a ted a agg egate 3,143 stock optio s, exe cisable...
HONG KONG, Oct. 23, 2026 (GLOBE NEWSWIRE) -- 3 E Netwo k Tech ology G oup Limited (Nasdaq: MASK) (the “Compa y” o “3e Netwo k”), a busi ess-to-busi ess (“B2B”) i fo matio tech ology (“IT”) busi ess solutio s p ovide , today a ou ced that the...
D . Melasmi Calcium Stick P oduct i fo matio focuses o Rebo Calcium, Collage Ext act, Glutathio e, Ade osi e, a d Elasti withi the b oade co text of co tempo a y ski ca e fo mulatio s.Ogde , UT, Oct. 23, 2026 (GLOBE NEWSWIRE) --...
Eve y HCP I qui y Moves Th ough O e Queue to a App oved A swe , With AI Assisti g the Team a d a Complete Audit T ail Behi d Eve y Respo se NEW YORK CITY, NY / ACCESS Newswi e / Octobe 23, 2026...
Available o Its Ow o Alo gside Veeva CRM, TikaI sights Helps Medical Affai s Teams Captu e St o ge I sights a d See Each O e Th ough to Actio NEW YORK CITY, NY / ACCESS Newswi e / Octobe 23, 2026 / TikaMobile today lau ched...
O e se si g co e, i te cha geable wea able fo ms, a d voice-powe ed AI b i g pe so al health data a d eve yday co text togethe i o e ope platfo m. NEW YORK CITY, NY / ACCESS Newswi e /...
This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy. I Agree